

## Striving for the best ...

Fresenius is a global health care group providing products and services for dialysis, hospitals and the medical care of patients at home. In addition, Fresenius focuses on clinic operations as well as on engineering and services for hospitals and other health care facilities. More than 137,000 employees are dedicated to the service of health in over 100 countries worldwide.



### SALES BY BUSINESS SEGMENT

€ millions	2010	2009	Change
Fresenius Medical Care	9,091	8,064	13 %
Fresenius Kabi	3,672	3,086	19 %
Fresenius Helios	2,520	2,416	4 %
Fresenius Vamed	713	618	15 %

## ... to benefit our patients

We recognize opportunities for growth in the advancement of our products and services, in consistent quality improvements, and in continuing international expansion. We are responding to the challenge of economizing efforts in the health care sector by means of therapeutic as well as medical product innovations and increased efficiency. Our aim is to further improve patients' quality of life around the world.

### FRESENIUS GROUP IN FIGURES

€ millions	2010	2009	2008
<b>Earnings</b>			
Sales	15,972	14,164	12,336
EBIT	2,418	2,054	1,727 <sup>1</sup>
EBIT margin	15.1 %	14.5 %	14.0 % <sup>1</sup>
Net income <sup>2</sup>	660 <sup>1</sup>	514 <sup>1</sup>	450 <sup>1</sup>
Operating cash flow	1,911	1,553	1,074
<b>Balance sheet</b>			
Total assets	23,577	20,882	20,544
Equity ratio <sup>3</sup>	38 %	36 %	34 %
Acquisitions	644	260	3,853
Investments <sup>4</sup>	758	671	764
<b>Employees (Dec. 31)</b>	<b>137,552</b>	<b>130,510</b>	<b>122,217</b>

<sup>1</sup> 2008 before special items from the APP acquisition; 2010 and 2009 adjusted for the effects of the mark-to-market accounting of the mandatory exchangeable bonds (MEBs) and contingent value rights (CVRs). Both are non-cash items.

<sup>2</sup> Net income attributable to Fresenius SE & Co. KGaA

<sup>3</sup> Equity including noncontrolling interest

<sup>4</sup> Investments in property, plant and equipment and intangible assets

### KEY DATA REGARDING FRESENIUS SHARES


	2010	2009	2008
Number of shares	162,450,090	161,315,376	161,143,734
Market capitalization <sup>1</sup>	10,301	7,538	6,270
Per share in €			
Dividend ordinary share	0.86	0.75	0.70
Dividend preference share	n.a.	0.76	0.71
Earnings per ordinary share	4.08 <sup>2</sup>	3.18 <sup>2</sup>	2.85 <sup>3</sup>
Earnings per preference share	4.08 <sup>2</sup>	3.19 <sup>2</sup>	2.86 <sup>3</sup>

<sup>1</sup> In million €, total number of ordinary and preference shares multiplied by the respective Xetra year-end quotation on the Frankfurt Stock Exchange


<sup>2</sup> Adjusted for special items resulting from changes in the market value (mark-to-market accounting) of the mandatory exchangeable bonds (MEBs) and contingent value rights (CVRs) in connection with the acquisition of APP Pharmaceuticals

<sup>3</sup> Before special items relating to the APP acquisition

### SALES BY REGION



### EMPLOYEES BY REGION



## FRESENIUS

**Corporate Headquarters**  
Else-Kröner-Strasse 1  
Bad Homburg v. d. H.  
Germany

**Postal address**  
Fresenius SE & Co. KGaA  
61346 Bad Homburg v. d. H.  
Germany

[www.fresenius.com](http://www.fresenius.com)

**Contact for journalists**  
Corporate Communications  
T +49 6172 608-2302  
F +49 6172 608-2294  
pr-fre@fresenius.com

**Contact for shareholders**  
Investor Relations  
T +49 6172 608-2637  
F +49 6172 608-2488  
ir-fre@fresenius.com

## FRESENIUS





DIALYSIS PRODUCTS,  
DIALYSIS CARE

Fresenius Medical Care is the world's leading provider of **products** and **services** for individuals undergoing dialysis because of chronic kidney failure. This condition affects more than two million patients worldwide. Through its network of 2,757 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 214,648 patients (as of Dec. 31, 2010). The company also provides a wide range of products for **hemodialysis** and **peritoneal dialysis** such as hemodialysis machines, dialyzers and related disposable products. Further information is available at: [www.fmc-ag.com](http://www.fmc-ag.com).

#### KEY FIGURES

	2010 US\$ millions	2009 US\$ millions	Change
Sales	12,053	11,247	7 %
EBIT	1,924	1,756	10 %
Net income <sup>1</sup>	979	891	10 %
Operating cash flow	1,368	1,339	2 %
Capital expenditure/acquisitions	1,314	766	72 %
R & D expenses	97	94	3 %
Employees (December 31)	77,442	71,617	8 %

<sup>1</sup> Attributable to Fresenius Medical Care AG & Co. KGaA



IV DRUGS, INFUSION THERAPY,  
CLINICAL NUTRITION,  
MEDICAL DEVICES/  
TRANSFUSION TECHNOLOGY

Fresenius Kabi is the market leader in **infusion therapy** and **clinical nutrition** in Europe and holds leading positions in the company's most important countries of Latin America and the Asia-Pacific region. In the field of **intravenously administered generic drugs** (IV drugs), Fresenius Kabi ranks among the leading global suppliers. The company is focused on the therapy and care of critically and chronically ill patients both in the hospital and home-care environments. Fresenius Kabi's portfolio comprises a wide range of IV drugs, infusion solutions, blood volume replacement products as well as parenteral (intravenously administered) and enteral (sip and tube feeds, administered through the gastrointestinal tract) nutrition products. To administer these products, Fresenius Kabi also offers the related medical devices. In addition, the company provides transfusion technology products for blood banks and blood donor centers.

#### KEY FIGURES

	2010 € millions	2009 € millions	Change
Sales	3,672	3,086	19 %
EBIT	737	607	21 %
Net income <sup>1</sup>	294	200	47 %
Operating cash flow	567	397	43 %
Capital expenditure/acquisitions	205	157	31 %
R & D expenses	143	129	11 %
Employees (December 31)	22,851	21,872	4 %

<sup>1</sup> Attributable to Fresenius Kabi AG



HOSPITAL OPERATIONS

Fresenius Helios is **one of the largest German private hospital operators**. The HELIOS Group operates 63 proprietary clinics altogether with more than 18,500 beds, including five maximum care clinics in Berlin-Buch, Erfurt, Krefeld, Schwerin and Wuppertal. In addition to 43 acute care clinics, Fresenius Helios owns 20 post-acute care clinics. Its goal is to provide high-quality, state-of-the-art treatment and care in all areas and at all care levels at its clinics. More than 33,000 employees treat more than two million patients – including approximately 600,000 inpatients – each year.

#### KEY FIGURES

	2010 € millions	2009 € millions	Change
Sales	2,520	2,416	4 %
EBIT	235	205	15 %
Net income <sup>1</sup>	131	107	22 %
Operating cash flow	311	219	42 %
Capital expenditure/acquisitions	179	203	-12 %
Employees (December 31)	33,321	33,364	0 %

<sup>1</sup> Attributable to HELIOS Kliniken GmbH



ENGINEERING AND SERVICES  
FOR HOSPITALS AND OTHER  
HEALTH CARE FACILITIES

Fresenius Vamed is a global provider of services in **planning, constructing** and **managing health care facilities**. The company offers hospitals a complete value chain to achieve and maintain efficiency at every stage: from project development, planning and turnkey construction to facility and total operational management. Headquartered in Vienna, Austria, Fresenius Vamed boasts a track record of approximately 500 completed health care projects in more than 60 countries since its founding in 1982. The approach of "everything from one source" has formed the cornerstone of Fresenius Vamed's reputation as a reliable partner in the health care industry.

#### KEY FIGURES

	2010 € millions	2009 € millions	Change
Sales	713	618	15 %
EBIT	41	36	14 %
Net income <sup>1</sup>	30	27	11 %
Operating cash flow	47	29	62 %
Capital expenditure/acquisitions	14	7	100 %
Order intake	625	539	16 %
Employees (December 31)	3,110	2,849	9 %

<sup>1</sup> Attributable to VAMED AG